BBIO vs INNV: fair value comparison
BridgeBio Pharma, Inc. and InnovAge Holding Corp. · Updated 2026-10-19
BBIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. INNV is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, INNV currently ranks higher by quality score.
| BBIO | INNV | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $66.39 | $8.85 |
| 12-month range | $53.81–$90.17 | $3.99–$12.11 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #133 of 301 Healthcare | #131 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: BBIO fair value analysis · INNV fair value analysis